2009

Encorium’s Q3 Revenue Falls 18%

Tuesday, November 17, 2009

Encorium Group, a CRO, reported third quarter revenue decreased 18% to $4.5 million but its loss from continuing operations narrowed to $643,389 or $(0.04) per diluted share for the third quarter of 2009, from a net loss of $2.4 million, or $(0.12) per diluted share, in the third quarter of 2008.

[Read More]

ICON Extends Lilly Strategic Agreement to Japan

Thursday, November 12, 2009

ICON has signed an extension to its strategic agreement with Eli Lilly and Company to manage the company’s clinical data management outside the U.S. This extension means that ICON will now also manage Lilly’s needs in Japan in addition to those in Europe, Canada, Latin America, Australia and Asia, which was originally agreed to in November 2008.

[Read More]

China Drug Agency Details Process Changes at ChinaTrials 2009

Tuesday, November 10, 2009

At the ChinaTrials 2009 conference in Beijing Monday, Dr. Yi Feng, director of Review Management, Center for Drug Evaluation (CDE) in China, laid out plans to implement a new GRP process. GRP is an acronym representing three “R” practices: Good Review Practice, Good Regulatory Practice and Good Registration Practice. It is expected that implementing GRP will greatly contribute to shortening drug review timelines in China. 

[Read More]